Evidence map›Paper›PMID 23975612›Full record

ArticleJournal of cancer survivorship : research and practice2014

Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada.

Claire de Oliveira, Karen E Bremner, Andy Ni, Shabbir M H Alibhai, Audrey Laporte, Murray D Krahn

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 5 pooled it
8.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 5 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Financial toxicity associated with a cancer diagnosis in publicly funded healthcare countries: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  5. Pooled it
  6. Article
  7. A prospective evaluation of patient perspectives and financial considerations during prostate cancer treatment decision-making.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023
    Article
  8. Predictors of prostate cancer survivors' engagement in self-management behaviors.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Characteristics associated with inter-individual variability in financial distress in patients with breast cancer prior to and for 12 months following surgery.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  13. Patient and family financial burden associated with cancer treatment in Canada: a national study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. The social and economic toll of cancer survivorship: a complex web of financial sacrifice.Journal of cancer survivorship : research and practice · 2019
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Claire de OliveiraDepartment of Social and Epidemiological Research, Centre for Addiction and Mental Health, 33 Russell Street, Room T414, Toronto, Ontario, M5S 2S1, Canada, claire.deoliveira@camh.ca.
Karen E Bremner
Andy Ni
Shabbir M H Alibhai
Audrey Laporte
Murray D Krahn
Toronto General Hospital · CAToronto Public Health · CACentre for Addiction and Mental Health · CAUniversity of North Carolina at Chapel Hill · US

Funding

Canadian Institutes of Health Research 53114
6 · The paper itself

Abstract

purposeTime and out-of-pocket (OOP) costs can represent a substantial burden for cancer patients but have not been described for long-term cancer survivors. We estimated these costs, their predictors, and their relationship to financial income, among a cohort of long-term prostate cancer (PC) survivors.

methodsA population-based, community-dwelling, geographically diverse sample of long-term (2-13 years) PC survivors in Ontario, Canada, was identified from the Ontario Cancer Registry and contacted through their referring physicians. We obtained data on demographics, health care resource use, and OOP costs through mailed questionnaires and conducted chart reviews to obtain clinical data. We compared mean annual time and OOP costs (2006 Canadian dollars) across clinical and sociodemographic characteristics and examined the association between costs and four groups of predictors (patient, disease, system, symptom) using two-part regression models.

resultsPatients' (N = 585) mean age was 73 years; 77 % were retired, and 42 % reported total annual incomes less than $40,000. Overall, mean time costs were $838/year and mean OOP costs were $200/year. Although generally low, total costs represented approximately 10 % of income for lower income patients. No demographic variables were associated with costs. Radical prostatectomy, younger age, poor urinary function, current androgen deprivation therapy, and recent diagnosis were significantly associated with increased likelihood of incurring any costs, but only urinary function significantly affected total amount.

conclusionsTime and OOP costs are modest for most long-term PC survivors but can represent a substantial burden for lower income patients. Even several years after diagnosis, PC-specific treatments and treatment-related dysfunction are associated with increased costs. IMPLICATIONS FOR CANCER SURVIVORS: Time and out-of-pocket costs are generally manageable for long-term PC survivors but can be a significant burden mainly for lower income patients. The effects of PC-specific, treatment-related dysfunctions on quality of life can also represent sources of expense for patients.

Indexed as

Cost of IllnessAdenocarcinomaAgedAge FactorsAndrogen AntagonistsAntineoplastic AgentsCombined Modality TherapyCosts and Cost AnalysisErectile DysfunctionHealth ExpendituresHumansIncomeInsurance CoverageIntestinal DiseasesMaleMiddle AgedAndrogen AntagonistsAntineoplastic Agents

Identifiers

PMID23975612
OpenAlexW2047678698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.